Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study

Table 3 Effect of HBV and HCV co-infections on ART attrition among HIV patients who initiated ART between 2010 and 2018 in Guangxi, China

Variables	Number of HIV patients	Attritions	Person-years (PY)	Attrition rate per 100 person-years (95% CI)	HR (95% CI)	P value	aHR^a (95% CI)	P value
Total	58,239	13,872	234,421.19	5.92 (5.82–6.01)
HIV	46,847	10,169	187,680.8	5.42 (5.32–5.52)	Reference		Reference
HIV + HBV	6,707	1,442	28,092.09	5.13 (4.87–5.39)	0.95 (0.90–1.01)	0.074	1.34 (1.27–1.42)	< 0.001
HIV + HCV	3,828	1,823	15,148.30	12.03 (11.50–12.57)	2.22 (2.11–2.33)	< 0.001	1.73 (1.61–1.87)	< 0.001
HIV + HBV + HCV	857	438	3500.00	12.51 (11.37–13.66)	2.31 (2.10–2.54)	< 0.001	2.07 (1.85–2.31)	< 0.001

CI, Confidence interval; HR, Hazard ratio; aHR, Adjusted hazard ratio; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus
^aAdjusted for Age, gender, marital status, route of HIV transmission, CD4 count before ART, WHO clinical stage before ART, initial first-line ART regimen, current ART regimen, duration of using TDF-containing regimens, calendar year of ART initiation

ISSN: 2049-9957